← Insider buys

BIIB

Biogen Inc. · Healthcare

Insiders sold $771K of Biogen Inc. in the last 12 months and bought none

$0Bought, 12 mo
$771KSold, 12 mo
$33.3BMarket cap

BIIB over the last year

No insider buys filed in this year

BIIB after insider buys

3 months after each buy, from the first price a copier could get.

2 buys have 3 months of prices so far. A record shows here at 3.

Congress

Members reported 37 trades in BIIB since 2023.

Every filing

64 insider filings since 2016, newest first

BIIBSell

Lloyd Minor · Director

$240K−30.6%Aug 5
BIIBSell

Priya Singhal · Head of Development

$532K−25.0%Feb 10
BIIBBuy

Caroline Dorsa · Director

$152K+5.0%May 5
BIIBSell

Priya Singhal · Head of Development

$88K−7.0%Sep 5
BIIBSell

Priya Singhal · Head of Development

$58K−5.0%Feb 26
BIIBBuy

Eric K Rowinsky · Director

$101K+2.0%Feb 20
BIIBSell

Priya Singhal · Head of Development

$100K−8.0%Feb 13
BIIBSell

Priya Singhal · Head of Development

$156K−13.0%Feb 5
BIIBSell

Priya Singhal · Head of Development

$27K−3.0%Dec 12
BIIBSell

Priya Singhal · Head of Development

$116K−11.0%Sep 6
BIIBSell

Ginger Gregory · EVP and HR

$804K−24.0%May 2
BIIBSell

Priya Singhal · Head of Development

$25K−3.0%Apr 6
BIIBSell

Priya Singhal · Head of Development

$153K−17.0%Mar 30
BIIBSell

Ginger Gregory · EVP and HR

$1.7M−50.0%Dec 12
BIIBSell

Susan H Alexander · EVP Chief Legal Off, Corp Sec

$1.6M−12.0%Oct 28
BIIBSell

Alfred Sandrock · Head of Research, Development

$3.4M−43.0%Jun 9
BIIBSell

Chirfi Guindo · Head of Glob Prod Strat, Com

$1.4M−51.0%Jun 9
BIIBSell

Brian S Posner · Director

$99K−5.0%Jun 7
BIIBBuy

Jesus B Mantas · Director

$240K+44.0%Feb 10
BIIBBuy

Michel Vounatsos · CEO

$748K+10.0%Dec 1
BIIBSell

Alfred Sandrock · EVP, Research, Development

$525K−10.0%Nov 6
BIIBSell

Stephen A Sherwin · Director

$719K−14.0%Mar 12
BIIBSell

Brian S Posner · Director

$308K−13.0%Dec 3
BIIBBuy

Alexander J Denner · Director

$27.2M+22.0%May 2
BIIBBuy

Michel Vounatsos · CEO

$1.0M+26.0%May 2
BIIBSell

Robert W Pangia · Director

$2.0M−25.0%Mar 19
BIIBBuy

Alexander J Denner · Director

$20.6M+13.0%Feb 1
BIIBSell

Michael D Ehlers · EVP, Research, Development

$350K−19.0%Sep 27
BIIBBuy

Alexander J Denner · Director

$13.0M+11.0%Apr 27
BIIBSell

Alfred Sandrock · EVP and Chief Medical Officer

$75K−4.0%Feb 28
BIIBSell

Alfred Sandrock · EVP and Chief Medical Officer

$266K−12.0%Feb 27
BIIBSell

Alfred Sandrock · EVP and Chief Medical Officer

$217K−10.0%Feb 21
BIIBSell

Alfred Sandrock · EVP and Chief Medical Officer

$387K−15.0%Feb 20
BIIBSell

Robert W Pangia · Director

$1.9M−25.0%Jan 10
BIIBBuy

Michel Vounatsos · CEO

$250K+19.0%Jan 2
BIIBBuy

Alexander J Denner · Director

$9.5M+8.0%Nov 30
BIIBSell

Susan H Alexander · EVP Chief Legal Corp Svc, Sec

$1.4M−18.0%Jul 26
BIIBSell

Susan H Alexander · EVP Chief Legal Corp Svc, Sec

$2.2M−22.0%Jul 20
BIIBSell

Brian S Posner · Director

$278K−15.0%Jun 12
BIIBBuy

Michel Vounatsos · CEO

$380K+92.0%May 2
BIIBBuy

Alexander J Denner · Director

$20.6M+23.0%May 1
BIIBSell

Paul J Clancy · EVP and CFO

$2.9M−48.0%Apr 27
BIIBSell

Alfred Sandrock · EVP CMO Neuro, Neurodegenerat

$543K−22.0%Apr 4
BIIBSell

Paul J Clancy · EVP and CFO

$2.9M−32.0%Mar 14
BIIBSell

Alfred Sandrock · EVP CMO Neuro, Neurodegenerat

$282K−10.0%Mar 3
BIIBBuy

Michel Vounatsos · CEO

$380KMar 1
BIIBSell

Robert W Pangia · Director

$1.6M−25.0%Jan 10
BIIBSell

Adriana Karaboutis · EVP, Tech, Bus. Sol, Corp Aff

$82K−3.0%Oct 5
BIIBSell

Adriana Karaboutis · EVP, Tech, Bus. Sol, Corp Aff

$119K−5.0%Oct 4
BIIBSell

Caroline Dorsa · Director

$8.7M−62.0%Sep 26
About Biogen Inc.

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.